SCHEMBL2768432

SCHEMBL2768432

CC(C)=CCCC(C)=C(C#N)c1ccccc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FNTA P49354 1/20 0.36
FNTB P49356 1/20 0.36
TRPV1 Q8NER1 2/20 0.36
PPARG P37231 1/20 0.36
PPARA Q07869 1/20 0.36
TSHR P16473 2/20 0.35
ICMT O60725 1/20 0.35
GMNN O75496 1/20 0.35
TRPA1 O75762 1/20 0.35
LMNA P02545 1/20 0.35
CYP1A2 P05177 1/20 0.35
POLB P06746 1/20 0.35
CYP3A4 P08684 1/20 0.35
MAPT P10636 1/20 0.35
CYP2C9 P11712 1/20 0.35
NFKB1 P19838 1/20 0.35
CDK2 P24941 1/20 0.35
RECQL P46063 1/20 0.35
BLM P54132 1/20 0.35
HIF1A Q16665 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2768625 1.00 FNTA (0.36) FNTAFNTBTRPV1PPARGPPARA
SCHEMBL2770069 0.78 TRPV1 (0.40) FNTAFNTBTRPV1PPARGPPARA
SCHEMBL2770071 0.78 TRPV1 (0.40) FNTAFNTBTRPV1PPARGPPARA
SCHEMBL2767639 0.75 ATM (0.41) LMNAPOLBMAPTRECQLESR1
SCHEMBL13990398 0.75 ATM (0.41) LMNAPOLBMAPTRECQLESR1
SCHEMBL2768577 0.75 ATM (0.41) LMNAPOLBMAPTRECQLESR1
SCHEMBL19063407 0.74 MCL1 (0.40) TSHRLMNAPOLBMAPTMEN1
SCHEMBL6236596 0.72 TRPV1 (0.43) FNTAFNTBTRPV1TSHRICMT
SCHEMBL11384039 0.71 KMT2A (0.43) FNTAFNTBTSHRPOLBCYP3A4
SCHEMBL14194446 0.70 KMT2A (0.46) LMNACYP1A2POLBMAPTCYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1824952-B1 ORGANIC COMPOUNDS GIVAUDAN SA (CH) 2010-04-28 EP claimed
US-20080306170-A1 Organic Compounds GIVAUDAN SA (CH) 2008-12-11 US claimed
EP-1824952-A1 ORGANIC COMPOUNDS Givaudan SA (CH) 2007-08-29 EP claimed
WO-2006060931-A1 ORGANIC COMPOUNDS GIVAUDAN SA (CH) 2006-06-15 WO claimed
US-9102899-B2 Organic compounds GIVAUDAN SA (CH) 2015-08-11 US disclosed
EP-1824952-B1 ORGANIC COMPOUNDS GIVAUDAN SA (CH) 2010-04-28 EP disclosed
US-20080306170-A1 Organic Compounds GIVAUDAN SA (CH) 2008-12-11 US disclosed
EP-1824952-A1 ORGANIC COMPOUNDS Givaudan SA (CH) 2007-08-29 EP disclosed
WO-2006060931-A1 ORGANIC COMPOUNDS GIVAUDAN SA (CH) 2006-06-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306170-A1 Organic Compounds PNN, TRPA1, PAOX FNTA 1910/4885FNTB 510/4885TRPV1 26/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.